Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

Endometrial cancer (EC) is the most common gynecological malignancy in developed countries, with its incidence steadily rising worldwide due to increasing ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

An unnerving trend is taking shape among cancer ... cells, especially their ability to create extra estrogen and thus amplify your risk of estrogen-influenced cancers like ovarian and endometrial.

Part of that spike is due to rising rates of cancers that affect primarily women, including breast cancer and endometrial cancer (a.k.a. cancer in the lining of the uterus), Rebecca Siegel, MPH, ...

On World Cancer Day 2025, learn about 10 warning signs of cancer you shouldn’t ignore, from unexplained weight loss to ...

New figures say there will be 3.4m people living with cancer in the UK by the end of 2025 - but the earlier it is spotted the better your survival chance ...

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...

Stopping smoking has been shown to allow cells that have avoided damage from the cancer-causing chemicals in tobacco smoke ..

Collaboration to take Cytovation's synthetic peptide, CY-101, into a Phase 2 trial for patients with adrenocortical carcinoma <li /> Ca ...

Estrogen is the reproductive hormone that causes the cells of the uterine lining ... connection between vaginal bleeding and endometrial cancer is clear, most people who have postmenopausal ...